Sectors

Cambrian Biopharma, LG, GlaxoSmithKline, Novo and Takeda all invested in the cell therapy developer to help it close its series C round.

Taiho has reupped its commitment to the venture firm’s second fund, which is also backed by EA Pharma and Senju and which has closed at $95m.

UGA spinout Aruna Bio is working on a treatment for neurodegenerative diseases such as Parkinson’s and multiple sclerosis.

ECBF has supplied an extension to Aphea.Bio’s series B round, which already included Gemma Frisius Fund, Qbic, Vives and V-Bio Ventures.

The insurer has made an initial $137m commitment to its newly formed Phoenix Venture Capital Partners unit, which will back ESG-minded entrepreneurs in the UK.

American Family and Cox Enterprises have helped the digital insurance provider reach a unicorn valuation and take its overall funding to $329m.

Vision Fund 2 participated in a series B round for the gene therapy developer, formed through the 2019 merger of Torque Therapeutics and Cogen Immune Medicine.

Vizgen co-founder David Walt, a professor at Harvard Medical School, has invested in the spinout as part of its series B round.

Gene therapy developer Jaguar has completed a series B round co-led by Eli Lilly and Deerfield Management.

Esri helped Allied Minds' satellite constellation operator take its total funding to $155m in a round that will fund the launch of more satellites.

ECBF has provided an extension for the pesticide and crop stimulant provider's Group De Ceuster-bacekd series B round, which now stands at $21.8m.